- Home
- PEPG vs ABEO Comparison
PEPG vs ABEO Comparison
Compare PEPG & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEPG
- ABEO
- Stock Information
- Founded
- PEPG 2018
- ABEO 1974
- Country
- PEPG United States
- ABEO United States
- Employees
- PEPG N/A
- ABEO N/A
- Industry
- PEPG Biotechnology: Pharmaceutical Preparations
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- PEPG Health Care
- ABEO Health Care
- Exchange
- PEPG Nasdaq
- ABEO Nasdaq
- Market Cap
- PEPG 317.6M
- ABEO 281.0M
- IPO Year
- PEPG 2022
- ABEO 1980
- Fundamental
- Price
- PEPG $4.51
- ABEO $4.99
- Analyst Decision
- PEPG Strong Buy
- ABEO Strong Buy
- Analyst Count
- PEPG 6
- ABEO 6
- Target Price
- PEPG $9.17
- ABEO $18.17
- AVG Volume (30 Days)
- PEPG 970.7K
- ABEO 1.1M
- Earning Date
- PEPG 11-06-2025
- ABEO 11-13-2025
- Dividend Yield
- PEPG N/A
- ABEO N/A
- EPS Growth
- PEPG N/A
- ABEO N/A
- EPS
- PEPG N/A
- ABEO 0.99
- Revenue
- PEPG N/A
- ABEO $400,000.00
- Revenue This Year
- PEPG N/A
- ABEO N/A
- Revenue Next Year
- PEPG N/A
- ABEO $324.71
- P/E Ratio
- PEPG N/A
- ABEO $5.05
- Revenue Growth
- PEPG N/A
- ABEO N/A
- 52 Week Low
- PEPG $0.88
- ABEO $3.93
- 52 Week High
- PEPG $7.62
- ABEO $7.54
- Technical
- Relative Strength Index (RSI)
- PEPG 52.66
- ABEO 33.78
- Support Level
- PEPG $4.36
- ABEO $5.29
- Resistance Level
- PEPG $5.65
- ABEO $5.61
- Average True Range (ATR)
- PEPG 0.40
- ABEO 0.24
- MACD
- PEPG -0.12
- ABEO 0.01
- Stochastic Oscillator
- PEPG 11.64
- ABEO 2.74
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.